Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply

N Engl J Med. 2025 Jun 5;392(21):2181. doi: 10.1056/NEJMc2503839.

Authors

Jennifer R Brown¹, Kara Miller², Veerendra Munugalavadla²

Affiliations

¹ Dana-Farber Cancer Institute, Boston.
² AstraZeneca, South San Francisco, CA.

PMID: 40466082
DOI: 10.1056/NEJMc2503839

No abstract available

Publication types

Letter
Comment